T-Lymphocyte Subsets in Patients with AJCC Stage III Gastric Cancer during Postoperative Adjuvant Chemotherapy

Cho, M. Y.; Joh, Yong Geul; Kim, N. R.; Jung, Seung Jin; Bae, Jeoung Won; Kim, Y. C.; Koo, Bum Hwan; Whang, Cheung Wung; Suh, Soon Yong

doi:10.1177/145749690209100207

Cited by 10 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found that the percentage of CD3 + cells and the ratio of CD4 + to CD8 + cells were lower than the normal reference values. Similar results have been reported previously by others [11]. We also found that the percentages of CD3 + , CD4 + cells, and the ratio of CD4 + /CD8 + were significantly higher 1 week after the first cycle of CIK-cell therapy but had declined markedly at 2 months.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer

Shi

Zhou

et al. 2012

Cancer Immunol Immunother

105

View full text Add to dashboard Cite

PurposeTo determine the long-term efficacy of adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells for locally advanced gastric cancer patients.Experimental designOne hundred and fifty-one patients with stage III/IV gastric cancer who had undergone gastrectomy were enrolled, assigned to two groups (immunotherapy group versus no immunotherapy group/or control group), and followed.ResultsThe 5-year overall survival (OS) and 5-year disease-free survival (DFS) rates for immunotherapy versus control group were 32.4 versus 23.4 % (P = 0.071) and 28.3 versus 10.4 % (P = 0.044), respectively. For patients with intestinal-type tumors, the 5-year OS and DFS rates were significantly higher for immunotherapy (OS, 46.8 vs. 31.4 % and P = 0.045; DFS, 42.4 vs. 15.7 % and P = 0.023). In the immunotherapy group, the mean CD3+ level, CD4+ level, and CD4+/CD8+ ratio increased from 50.8, 26.5, and 0.9 %, respectively, at baseline to 62.6, 35.0, and 1.4 %, respectively, 1 week after the first CIK-cell treatment, returned to baseline after 2 months, and maintained a higher level (60.7 ± 8.2 %, 34.2 ± 7.1 %, and 1.3 ± 0.3 %, respectively) 2 months after 3 cycles of immunotherapy.ConclusionsAdjuvant immunotherapy with CIK cells prolongs DFS in patients with locally advanced gastric cancer and significantly improves OS in patients with intestinal-type tumors. Intestinal-type tumors could be selected as an important indication for CIK-cell therapy. This treatment may help improve T-lymphocyte subset distribution and improve the host’s immune functions, but multiple cycles are necessary for long-term therapeutic efficacy.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Immunosuppression may be more serious after surgery for the treatment for malignant diseases, including gastric cancer [11]. After adjuvant chemotherapy, the host’s immune functions would be expected to be further damaged because most chemotherapeutic agents are immunosuppressive.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer

Shi

Zhou

et al. 2012

Cancer Immunol Immunother

105

View full text Add to dashboard Cite

show abstract

“…In the present study, the number of CD3 + and CD4 + cells was significantly increased, while the number of CD8 + cells was declined and the CD4 + /CD8 + ratio was increased after CIK cells immunotherapy, suggesting that CIK cells also have an immune modulating function in addition to their anti-tumor function [50] . Single CIK cells immunotherapy has an in vivo effect against gastric cancer for about one month [51] . In contrast, the number of CD3 + cells and the CD4 + /CD8 + ratio maintain at a high level after three cycles of CIK cells immunotherapy [17] .…”

Section: Discussionmentioning

confidence: 99%

Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients

Jiang

Shen²,

Wu³

et al. 2010

WJG

View full text Add to dashboard Cite

show abstract

“…However, no significant differences were found in the percentages of CD4 + , CD8 + and CD4 + /CD8 + ratios before and after immunotherapy. This may be caused by the different time points when the T-lymphocyte subsets were tested in these trials 6,19,42,43. Our analysis revealed a decreased proportion of CD4 + CD25 + CD127 − Tregs.…”

Section: Discussionmentioning

confidence: 76%

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis

Liu

Mu²,

Zhang

et al. 2017

OTT

View full text Add to dashboard Cite

BackgroundImmunotherapy based on cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising clinical outcomes for treating esophageal cancer (EC). However, the clinical benefit varies among previous studies. Therefore, it is necessary to systematically evaluate the curative efficacy and safety of CIK/DC-CIK immunotherapy as an adjuvant therapy for conventional therapeutic strategies in the treatment of EC.Materials and methodsClinical trials published before October 2016 and reporting CIK/DC-CIK immunotherapy treatment responses or safety for EC were searched in Cochrane Library, EMBASE, PubMed, Wanfang and China National Knowledge Internet databases. Research quality and heterogeneity were evaluated before analysis, and pooled analyses were performed using random- or fixed-effect models.ResultsThis research covered 11 trials including 994 EC patients. Results of this meta-analysis indicated that compared with conventional therapy, the combination of conventional therapy with CIK/DC-CIK immunotherapy significantly prolonged the 1-year overall survival (OS) rate, overall response rate (ORR) and disease control rate (DCR) (1-year OS: P=0.0005; ORR and DCR: P<0.00001). Patients with combination therapy also showed significantly improved quality of life (QoL) (P=0.02). After CIK/DC-CIK immunotherapy, lymphocyte percentages of CD3+ and CD3−CD56+ subsets (P<0.01) and cytokines levels of IFN-γ, -2, TNF-α and IL-12 (P<0.00001) were significantly increased, and the percentage of cluster of differentiation (CD)4+CD25+CD127− subset was significantly decreased, whereas analysis of CD4+, CD8+, CD4+/CD8+ and CD3+CD56+ did not show significant difference (P>0.05).ConclusionThe combination of CIK/DC-CIK immunotherapy and conventional therapy is safe and markedly prolongs survival time, enhances immune function and improves the treatment efficacy for EC.

show abstract

T-Lymphocyte Subsets in Patients with AJCC Stage III Gastric Cancer during Postoperative Adjuvant Chemotherapy

Abstract: The results of this study suggest that immunosuppression associated with CD3+ and CD4+ T-cell depression is a risk factor for postoperative recurrence in patients with stage III gastric cancer.

Cited by 10 publications

References 18 publications

Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer

Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer

Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis

Contact Info

Product

Resources

About